media: Merck’s $1 billion deal includes phase 3 ovarian cancer therapeutic (Vintafolide/Endocyte)

Merck’s $1 billion deal includes phase 3 ovarian cancer therapeutic

 Merck (NYSE:MRK) has forged a deal with a biopharmaceutical company for its phase 3 platinum-resistant ovarian cancer treatment and nonsmall cell lung cancer in mid-stage development in a deal valued at up to $1 billion... Under the terms of the deal, Merck, through a subsidiary, will get worldwide rights to develop and commercialize vintafolide for ovarian cancer that’s resistant to platinum-based chemotherapy treatment. Endocyte (NASDAQ:ECYT), the Indiana-based cancer therapeutics developer, will receive a $120 million up-front payment and is eligible for milestone payments of up to $880 million if it achieves certain development, regulatory and commercialization milestones for vintafolide for a total of six cancer indications, according to a company statement......

"...The clinical trials for both maladies will also use etarfolatide, a noninvasive companion diagnostic imaging agent that is used to identify folate receptor positive tumor cells.....

Endocyte jumps on plans for cancer drug candidate - Bioscience Technology (EC145 vs Doxil - re: Doxil drug shortage....)

Endocyte jumps on plans for cancer drug candidate - Bioscience Technology:

The Inquisitr

Endocyte jumps on plans for cancer drug candidate Bioscience Technology The study is designed to compare EC145 to the chemotherapy drug Doxil as a treatment for ovarian cancer. Enrollment stopped because of a shortage of Doxil, and the company said Tuesday that the Food and Drug Administration will allow it to import the ... Endocyte Prepares To Restart Clinical Trials For Experimental Cancer DrugThe Inquisitr Endocyte to seek European OK for ovarian cancer drugIndianapolis Star Endocyte to Submit EU Conditional Marketing Authorization Applications for ...MarketWatch (press release) Wall Street Journal -Indianapolis Business Journal all 21 news articles »